Drug Profile


Alternative Names: MDL 19205

Latest Information Update: 17 Apr 1996

Price : $50

At a glance

  • Originator Aventis
  • Class Anti-ischaemics; Cardiotonics; Imidazoles; Small molecules; Vasodilators
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 17 Apr 1996 Discontinued-Preclinical for Heart failure in Japan (Unknown route)
  • 17 Apr 1996 Discontinued-II for Heart failure in Germany (Unknown route)
  • 17 Apr 1996 Discontinued-III for Heart failure in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top